Statin safety: lessons from new drug applications for marketed statins.
about
Jupiter to earth: a statin helps people with normal LDL-C and high hs-CRP, but what does it mean?Muscular effects of statins in the elderly female: a reviewA prospective stratified case-cohort study on statins and multiple adverse events in Japan.Statins in the treatment of dyslipidemia in the presence of elevated liver aminotransferase levels: a therapeutic dilemma.Niacin or ezetimibe for patients with, or at risk of coronary heart diseaseDrug-related myopathies of which the clinician should be awareApplication of chrysophanol in zebrafish to reduce dietary introduced lipid and its possible mechanism.Individualized risk for statin-induced myopathy: current knowledge, emerging challenges and potential solutionsLipid-lowering agents that cause drug-induced hepatotoxicity.Protective effects of coenzyme q(10) on decreased oxidative stress resistance induced by simvastatin.Relative safety profiles of high dose statin regimens.Simvastatin: present and future perspectives.The safety of rosuvastatin: effects on renal and hepatic function.Rational approach to the treatment for heterozygous familial hypercholesterolemia in childhood and adolescence: a review.Efficacy, effectiveness and real life goal attainment of statins in managing cardiovascular riskLipidomics-based safety biomarkers for lipid-lowering treatments.Statins and succinylcholine interaction: A cause of concern for serious muscular damage in anesthesiology practice!Does simvastatin cause more myotoxicity compared with other statins?A systematic review and meta-analysis on the therapeutic equivalence of statins.Event reduction: revisiting why we treat with statins and harnessing current evidence towards optimal therapy.Chronic obstructive pulmonary disease: patho-physiology, current methods of treatment and the potential for simvastatin in disease management.Clinical response to statins: mechanism(s) of variable activity and adverse effects.Genetics and personalized medicine--a role in statin therapy?Statins and Nonadherence: Should We RELATE Better?Statin therapy across the lifespan: evidence in major age groups.Pharmacologic Treatment of Dyslipidemia in Diabetes: A Case for Therapies in Addition to Statins.Statin myopathy: a lipid clinic experience on the tolerability of statin rechallenge.Can cheap generic statins achieve national cholesterol lowering targets?Effect of simvastatin and naringenin coadministration on rat liver DNA fragmentation and cytochrome P450 activity: an in vivo and in vitro study.Association between a frequent allele of the gene encoding OATP1B1 and enhanced LDL-lowering response to fluvastatin therapy.Food Effect on Rosuvastatin Disposition and Low-Density Lipoprotein Cholesterol.Continued statin therapy could improve the outcome after spontaneous intracerebral hemorrhage.Chronic kidney disease: Statins in chronic kidney disease: time to move on?Metabolomic strategies to identify tissue-specific effects of cardiovascular drugs
P2860
Q24630160-30A4898E-429C-4B89-9CE0-BDB9BFFB0E2EQ27023343-381A4AC2-DBFD-451C-89E2-CF2A9279DFFAQ33584216-2CF68B6E-B288-4955-9C52-C9EC9C68A4C7Q33765060-E47B9F49-DF34-4B2B-844D-CE3D7CF6D5A1Q34300722-143215C5-5847-4E49-A4A5-2D450AA863F9Q34974845-55B9B493-AF18-4875-AAC7-612F5679642CQ35778877-795012C1-B45E-4289-9B84-20AA160F5FE7Q35915932-75896385-2131-4CCC-8CA4-5EF78ACB2706Q36103339-3C1A7D80-2918-4E42-8EE2-ED17F7F49858Q36510647-D328F726-CE52-427A-9F9E-77D778773BD4Q36835823-AEFC91C6-0D60-475E-AEF1-CCCC2E79AE53Q36916934-75A81EC6-EF18-4551-BE67-E5EAD14056D3Q36945023-1A930F3A-F08D-437E-8201-FC3006009F6CQ36965617-5FA82D1F-3B79-4905-9C7F-80C4E62C1348Q37202135-BEEFE119-FA16-4154-9B5D-21A64D4FB79DQ37218576-232CE5B5-44B2-49EF-9B45-C9F400EED746Q37382024-E557067C-ED86-4CD4-8099-8D4FA41D02E4Q37634190-DF98C0D9-4CED-4909-B7D0-3560CBEFCBCDQ37747986-CEE545EC-8CE7-4167-BA92-E5A94742CDE3Q37812387-B4A56D83-7FE0-40F2-8574-527CCC3F172DQ37880077-286EB318-951D-467A-ABF1-53F5612361FAQ37881964-FD8670EE-C5B9-443E-8EDE-5F7D958FFF0CQ38167710-3975B529-4275-4220-8D47-0A80023BD15CQ38398011-68196BA1-1155-4F7B-A9D8-86AA321A9EB4Q38660929-C78ADB27-C447-41E0-A1C5-70C5702B4547Q39320400-B9479255-5720-4A0B-9194-75E86654EE0FQ39711727-F7FE65ED-56FB-4D93-BB5B-8C27DB8C9343Q44200883-14DED2C8-6545-4468-86F5-702362B3BAC0Q45941941-011B00A0-E09A-4717-B96E-5A6EE7FE0A51Q46378129-7999D5CC-12F8-4664-B388-23E5E332E7FEQ50016659-9DBA99CD-AA84-48EE-802D-53E7F679DD8BQ50901675-9E6D9BAC-4EE9-4EC6-B8E5-65C8474897DBQ53567966-B1363F6A-E907-4640-A677-8BB014308166Q57012269-C08749B8-9228-4F4D-AAA6-50537C7D9205
P2860
Statin safety: lessons from new drug applications for marketed statins.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Statin safety: lessons from new drug applications for marketed statins.
@ast
Statin safety: lessons from new drug applications for marketed statins.
@en
type
label
Statin safety: lessons from new drug applications for marketed statins.
@ast
Statin safety: lessons from new drug applications for marketed statins.
@en
prefLabel
Statin safety: lessons from new drug applications for marketed statins.
@ast
Statin safety: lessons from new drug applications for marketed statins.
@en
P1476
Statin safety: lessons from new drug applications for marketed statins
@en
P2093
Terry A Jacobson
P304
P356
10.1016/J.AMJCARD.2005.12.009
P407
P577
2006-02-02T00:00:00Z